The explosion of immuno-oncology
The differences in treating older versus younger CLL patients
Subcutaneous rituximab versus intravenous rituximab – safety and efficacy results
BGB-3111 and ibrutinib for Waldenström’s macroglobulinemia
What are the advantages of using histamine dihydrochloride together with immunotherapy?